Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?BERNHOLTZ, Shiri; LAITMAN, Yael; KAUFMAN, Bella et al.Breast cancer research and treatment. 2012, Vol 132, Num 2, pp 669-673, issn 0167-6806, 5 p.Article

Nasal Intermittent Mandatory Ventilation Versus Nasal Continuous Positive Airway Pressure for Respiratory Distress Syndrome : A Randomized, Controlled, Prospective StudyKUGELMAN, Amir; FEFERKORN, Ido; RISKIN, Arieh et al.The Journal of pediatrics. 2007, Vol 150, Num 5, pp 521-526, issn 0022-3476, 6 p.Article

First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA StudyTHOMSSEN, Christoph; PIERGA, Jean-Yves; PRITCHARD, Kathleen I et al.Oncology. 2012, Vol 82, Num 4, pp 218-227, issn 0030-2414, 10 p.Article

Male breast carcinoma in Israel: Higher incidence but possibly better prognosis in Ashkenazi JewsBRENNER, Baruch; FRIED, Georgeta; LEVITZKI, Pavel et al.Cancer. 2002, Vol 94, Num 8, pp 2128-2133, issn 0008-543XArticle

Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: Effects of oral contraceptive use and parental origin of mutationBERNHOLTZ, Shiri; LAITMAN, Yael; KAUFMAN, Bella et al.Breast cancer research and treatment. 2011, Vol 129, Num 2, pp 557-563, issn 0167-6806, 7 p.Article

The CYP17A1 ―34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriersKAUFMAN, Bella; LAITMAN, Yael; HUZARSKI, Tomasz et al.Breast cancer research and treatment. 2011, Vol 126, Num 2, pp 521-527, issn 0167-6806, 7 p.Article

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM StudyKAUFMAN, Bella; MACKEY, John R; REVIL, Cédric et al.Journal of clinical oncology. 2009, Vol 27, Num 33, pp 5529-5537, issn 0732-183X, 9 p.Article

Association Between Standard Clinical and Pathologic Characteristics and the 21-Gene Recurrence Score in Breast Cancer Patients : A Population-based StudyWOLF, Ido; BEN-BARUCH, Noa; SHAPIRA-FROMMER, Ronnie et al.Cancer. 2008, Vol 112, Num 4, pp 731-736, issn 0008-543X, 6 p.Article

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab : updated efficacy and biomarker analysesCAMERON, David; CASEY, Michelle; CHAN, Arlene et al.Breast cancer research and treatment. 2008, Vol 112, Num 3, pp 533-543, issn 0167-6806, 11 p.Article

Epigenetic silencing of the tumor suppressor klotho in human breast cancerRUBINEK, Tami; SHULMAN, Michal; ISRAELI, Shira et al.Breast cancer research and treatment. 2012, Vol 133, Num 2, pp 649-657, issn 0167-6806, 9 p.Article

KL1 Internal Repeat Mediates Klotho Tumor Suppressor Activities and Inhibits bFGF and IGF-I Signaling in Pancreatic CancerABRAMOVITZ, Lilach; RUBINEK, Tamar; LIGUMSKY, Hagai et al.Clinical cancer research (Print). 2011, Vol 17, Num 13, pp 4254-4266, issn 1078-0432, 13 p.Article

Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriersANTONIOU, Antonis C; SINILNIKOVA, Olga M; NEUHAUSEN, Susan L et al.Human molecular genetics (Print). 2009, Vol 18, Num 22, pp 4442-4456, issn 0964-6906, 15 p.Article

Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib MonotherapyJOHNSTON, Stephen; TRUDEAU, Maureen; HARRIS, Jennifer et al.Journal of clinical oncology. 2008, Vol 26, Num 7, pp 1066-1072, issn 0732-183X, 7 p.Article

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian CancerKAYE, Stan B; LUBINSKI, Jan; SAFRA, Tamar et al.Journal of clinical oncology. 2012, Vol 30, Num 4, pp 372-379, issn 0732-183X, 8 p.Article

Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriersCOX, David G; SIMARD, Jacques; SZABO, Csilla et al.Human molecular genetics (Print). 2011, Vol 20, Num 23, pp 4732-4747, issn 0964-6906, 16 p.Article

Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patientsWOLF, Ido; SADETZKI, Seigal; KANETY, Hannah et al.Cancer. 2006, Vol 106, Num 4, pp 966-973, issn 0008-543X, 8 p.Article

Association between diabetes mellitus and adverse characteristics of breast cancer at presentationWOLF, Ido; SADETZKI, Siegal; GLUCK, Iris et al.European journal of cancer (1990). 2006, Vol 42, Num 8, pp 1077-1082, issn 0959-8049, 6 p.Article

Lapatinib plus capecitabine for HER2-positive advanced breast cancerGEYER, Charles E; FORSTER, John; SKARLOS, Dimosthenis et al.The New England journal of medicine. 2006, Vol 355, Num 26, pp 2733-2743, issn 0028-4793, 11 p.Article

Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional StudyJOO ERN ANG; GOURLEY, Charlie; BANERJEE, Susana et al.Clinical cancer research (Print). 2013, Vol 19, Num 19, pp 5485-5493, issn 1078-0432, 9 p.Article

A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation CarriersDING, Yuan C; MCGUFFOG, Lesley; KRISTOFFERSSON, Ulf et al.Cancer epidemiology, biomarkers & prevention. 2012, Vol 21, Num 8, pp 1362-1370, issn 1055-9965, 9 p.Article

Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in IsraelLAITMAN, Yael; SIMEONOV, Monica; HERSKOVITZ, Liron et al.Breast cancer research and treatment. 2012, Vol 133, Num 3, pp 1153-1157, issn 0167-6806, 5 p.Article

The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cellsLIGUMSKY, Hagai; WOLF, Ido; ISRAELI, Shira et al.Breast cancer research and treatment. 2012, Vol 132, Num 2, pp 449-461, issn 0167-6806, 13 p.Article

Common alleles at 6q25.1 and 1 p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriersANTONIOU, Antonis C; KARTSONAKI, Christiana; ZAFFARONI, Daniela et al.Human molecular genetics (Print). 2011, Vol 20, Num 16, pp 3304-3321, issn 0964-6906, 18 p.Article

Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in IsraelLAITMAN, Yael; TSIPORA BORSTHEIN, Roni; ZIDAN, Jamal et al.Breast cancer research and treatment. 2011, Vol 127, Num 2, pp 489-495, issn 0167-6806, 7 p.Article

Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomyPIERCE, Lori J; PHILLIPS, Kelly-Anne; MERAJVER, Sofia D et al.Breast cancer research and treatment. 2010, Vol 121, Num 2, pp 389-398, issn 0167-6806, 10 p.Article